15
66M
12
4
0.20
3
- Areas of investment
Summary
The venture was found in Asia in China. The main department of described VC is located in the Shanghai.
Among the most popular fund investment industries, there are Software, Medical. Among the most popular portfolio startups of the fund, we may highlight Innovent Biologics, Ultivue, TenNor Therapeutics. The fund has no exact preference in some founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China.
The fund is constantly included in less than 2 deals per year. This Frontline BioVentures works on 4 percentage points more the average amount of lead investments comparing to the other organizations. Considering the real fund results, this VC is 30 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2015. The increased amount of exits for fund were in 2018.
The standard case for the fund is to invest in rounds with 4 partakers. Despite the Frontline BioVentures, startups are often financed by F-Prime Capital, Lilly Asia Ventures, Hansjoerg Wyss. The meaningful sponsors for the fund in investment in the same round are Yonghua Capital, WuXi Healthcare Ventures, Temasek Holdings. In the next rounds fund is usually obtained by Temasek Holdings, Taikang Life Insurance, Legend Capital.
The current fund was established by Lianyong Chen. We also calculated 1 valuable employee in our database.
Investments analytics
Analytics
- Total investments
- 15
- Lead investments
- 4
- Exits
- 3
- Follow on index
- 0.20
- Investments by industry
- Health Care (8)
- Biotechnology (5)
- Medical (4)
- Manufacturing (4)
- Pharmaceutical (3) Show 14 more
- Investments by region
-
- China (12)
- United States (3)
- Peak activity year
- 2014
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 14
- Avg. valuation at time of investment
- 70M
- Group Appearance index
- 0.67
- Strategy success index
- 0.50
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Coherent Biopharma | 01 Feb 2016 | Early Stage Venture | 8M | Jiangsu, Suzhou, China |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.